Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | PDE1A | P54750 | 2/20 | 0.61 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.61 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.61 |
| ▸ | SCD | O00767 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23131530 | 0.92 | KDM4E (0.63) | PDE5AKDM4ERAB9ASMN1; SMN2PDE1A | |
| SCHEMBL23131723 | 0.89 | RAB9A (0.82) | PDE5AKDM4ERAB9ASMN1; SMN2PDE1A | |
| SCHEMBL25720785 | 0.84 | PDE5A (0.79) | PDE5AKDM4ERAB9ASMN1; SMN2PDE1A | |
| SCHEMBL27599948 | 0.83 | KDM4E (0.78) | PDE5AKDM4ERAB9ASMN1; SMN2PDE1A | |
| SCHEMBL27782868 | 0.81 | AOC3 (0.74) | PDE5AKDM4ERAB9ASMN1; SMN2PDE1A | |
| SCHEMBL5717620 | 0.81 | KDM4E (0.74) | PDE5AKDM4ERAB9ASMN1; SMN2PDE1A | |
| SCHEMBL23131529 | 0.79 | KDM4E (0.67) | PDE5AKDM4ERAB9ASMN1; SMN2PDE1A | |
| SCHEMBL24101681 | 0.79 | PDE5A (0.70) | PDE5AKDM4ERAB9ASMN1; SMN2PDE1A | |
| SCHEMBL7454854 | 0.79 | ROCK2 (0.62) | PDE5AKDM4ESCDALDH1A1 | |
| SCHEMBL5875866 | 0.78 | ALDH1A1 (0.60) | KDM4ERAB9AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201339-A1 | USE OF THIAZOLE AMIDE COMPOUNDS FOR MODULATING HUMAN IMMUNE RESPONSE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230201339-A1 | USE OF THIAZOLE AMIDE COMPOUNDS FOR MODULATING HUMAN IMMUNE RESPONSE | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201339-A1 | USE OF THIAZOLE AMIDE COMPOUNDS FOR MODULATING HUMAN IMMUNE RESPONSE | MYD88, IRF3, TLR1 | PDE5A 738/4885KDM4E 3910/4885RAB9A 2035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.